PIERGENTILI, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.821
EU - Europa 6.640
AS - Asia 5.787
SA - Sud America 676
Continente sconosciuto - Info sul continente non disponibili 410
AF - Africa 232
OC - Oceania 51
Totale 30.617
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.248
CN - Cina 2.382
SG - Singapore 1.661
RU - Federazione Russa 1.489
IT - Italia 1.279
DE - Germania 1.053
BR - Brasile 558
VN - Vietnam 471
PL - Polonia 458
HK - Hong Kong 444
CA - Canada 439
GB - Regno Unito 410
UA - Ucraina 395
SE - Svezia 392
FI - Finlandia 354
FR - Francia 342
ZA - Sudafrica 165
TR - Turchia 161
KR - Corea 143
IN - India 121
IE - Irlanda 106
CZ - Repubblica Ceca 86
BD - Bangladesh 84
JP - Giappone 79
MX - Messico 60
NL - Olanda 60
BE - Belgio 55
AU - Australia 48
AR - Argentina 41
EU - Europa 37
ES - Italia 36
IQ - Iraq 34
IR - Iran 31
PK - Pakistan 29
EC - Ecuador 22
EG - Egitto 19
CO - Colombia 17
ID - Indonesia 17
LT - Lituania 16
HR - Croazia 14
JM - Giamaica 14
MA - Marocco 14
RO - Romania 14
AE - Emirati Arabi Uniti 13
AT - Austria 13
CR - Costa Rica 12
PH - Filippine 12
SA - Arabia Saudita 12
CH - Svizzera 11
MY - Malesia 10
RS - Serbia 10
UZ - Uzbekistan 10
VE - Venezuela 10
IL - Israele 9
TW - Taiwan 8
AL - Albania 7
CL - Cile 7
DZ - Algeria 7
GT - Guatemala 7
JO - Giordania 7
KE - Kenya 7
PE - Perù 7
HN - Honduras 6
NP - Nepal 6
PT - Portogallo 6
PY - Paraguay 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
AZ - Azerbaigian 5
BY - Bielorussia 5
EE - Estonia 5
GP - Guadalupe 5
GR - Grecia 5
NI - Nicaragua 5
PA - Panama 5
SN - Senegal 5
TH - Thailandia 5
CW - ???statistics.table.value.countryCode.CW??? 4
HU - Ungheria 4
KG - Kirghizistan 4
KH - Cambogia 4
TN - Tunisia 4
BG - Bulgaria 3
DO - Repubblica Dominicana 3
GE - Georgia 3
IS - Islanda 3
KZ - Kazakistan 3
NG - Nigeria 3
PR - Porto Rico 3
QA - Qatar 3
SV - El Salvador 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AD - Andorra 2
BS - Bahamas 2
DK - Danimarca 2
GA - Gabon 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LV - Lettonia 2
NZ - Nuova Zelanda 2
Totale 30.223
Salva come PNG Salva come JPEG
Città #
Ashburn 1.457
Dallas 1.350
Woodbridge 1.039
Jacksonville 960
Fairfield 955
Singapore 914
San Jose 800
Chandler 756
Ann Arbor 600
Houston 578
Wilmington 541
Council Bluffs 517
Hong Kong 431
Beijing 416
Boardman 405
Seattle 395
Nanjing 333
Warsaw 316
Cambridge 308
Los Angeles 275
New York 253
Toronto 249
Dearborn 233
Camerino 208
Helsinki 174
Ho Chi Minh City 169
The Dalles 169
Düsseldorf 153
San Mateo 152
Johannesburg 149
Seoul 138
Princeton 134
Tongling 134
Kraków 129
Lawrence 128
Columbus 127
Santa Clara 124
Lauterbourg 121
Istanbul 119
Nanchang 116
Buffalo 109
Munich 107
Dublin 105
Orem 104
Hanoi 103
Moscow 100
Ogden 97
London 88
Kunming 86
Milan 82
Lachine 80
Phoenix 80
Shanghai 79
Shenyang 74
São Paulo 68
Brno 66
Chicago 62
Tokyo 58
Guangzhou 57
Jiaxing 57
Turku 54
Tianjin 53
Brussels 52
Jinan 50
Washington 46
Venezia 45
Hebei 44
Chennai 42
Frankfurt am Main 42
Brooklyn 41
Changsha 39
Denver 39
Montreal 39
Hangzhou 38
San Diego 38
Philadelphia 36
Redwood City 34
Rome 34
Manchester 33
Poplar 33
Zhengzhou 33
Stockholm 32
Wuhan 30
Atlanta 29
Boston 28
Falls Church 28
Hefei 27
St Louis 27
Mexico City 26
Leawood 25
Da Nang 24
Nuremberg 24
Trieste 24
Venice 24
Amsterdam 23
Ascoli Piceno 23
San Francisco 23
Taizhou 22
Centro 21
Ningbo 21
Totale 19.533
Salva come PNG Salva come JPEG
Nome #
1,4-Dioxane nucleus as a suitable scaffold in the building of ligands interacting with NMDA and σ1 receptors 671
1,4-DIOXANE NUCLEUS AS A SUITABLE SCAFFOLD FOR NOVEL D2-LIKE RECEPTOR LIGANDS 649
1,4-Dioxane, a Suitable Scaffold for the Development of Novel M3 Muscarinic Receptor Antagonists 640
1,4-Dioxane ring as a promising template of novel 5-HT1A full agonists 580
1'-Benzyl-3,4-dihydrospiro[2H-1-benzothiopyran-2,4'-piperidine] (Spipethiane), a potent and highly selective sigma1 lingand 576
Roles of Wnt/β-catenin signalling pathway in the bony repair of injured growth plate cartilage in young rats 475
Antagonism/Agonism modulation to build novel antihypertensives selectively triggering i1-imidazoline receptor activation 349
The Versatile 2-Substituted Imidazoline Nucleus as a Structural Motif of Ligands Directed to the Serotonin 5-HT1A Receptor 341
1-[3-(4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1) as a Model for the Rational Design of a Novel Class of Brain Penetrant Ligands with High Affinity and Selectivity for Dopamine D4 Receptor 341
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 337
Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring 323
TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation 310
A Novel Class of Dopamine D4 Receptor Ligands Bearing an Imidazoline Nucleus 310
Combined Interactions with I1-, I2-Imidazoline Binding Sites and α2-Adrenoceptors To Manage Opioid Addiction 304
Novel ligands rationally designed for characterizing I2-imidazoline binding sites nature and functions 293
2-(2-Phenylcyclopropyl)imidazolines: Reversed Enantioselective Interaction at I1 and I2 Imidazoline Receptors 282
33rd camerino-Cyprus Symposium - Receptor Chemistry: Reality and Vision 280
Synthesis and antimuscarinic activity of derivatives of 2-substituted-1,3-dioxolanes 280
Novel antitumor copper(ii) complexes designed to act through synergistic mechanisms of action, due to the presence of an NMDA receptor ligand and copper in the same chemical entity 277
Investigation of the Role of Chirality in the Interaction with σ Receptors and Effect on Binge Eating Episode of a Potent σ1 Antagonist Analogue of Spipethiane 270
The replacement of the 2-methoxy substituent of N-((6,6-diphenyl-1,4-dioxan-2-yl)methyl)-2-(2-methoxyphenoxy)ethan-1-amine improves the selectivity for 5-HT1A receptor over α1-adrenoceptor and D2-like receptor subtypes 265
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement. 259
Design, synthesis and muscarinic activity of deoxamuscarine-related derivatives 259
Multitarget 1,4-Dioxane Compounds Combining Favorable D2-like and 5-HT1A Receptor Interactions with Potential for the Treatment of Parkinson's Disease or Schizophrenia 256
alpha(2)-Adrenoreceptors profile modulation. 2. Biphenyline analogues as tools for selective activation of the alpha2C-subtype 252
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease 251
14th Camerino-Noordwijkerhout Symposium - Ongoing Progress in Receptor Chemistry 248
Binding of nicotine and homoazanicotine analogues at neuronal nicotinic acetylcholinergic (nACh) receptors 246
Identification of 2-aminopyrimidine derivatives as inhibitors of the canonical Wnt signaling pathway 243
Deoxamuscaroneoxime Devatives as useful Muscarinic Aginist to Explore the Muscarinic Subsite: Demox, Amodulator of Orthosteric and Allosteric Site at Cardiac Muscarinic M2 Receptors. 241
Inhibition of WNT-β-catenin signalling promotes cartilage repair at injured growth plate in young rats 239
Imidazoline binding sites (IBS) profile modulation: Key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues 239
Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites 236
33rd Camerino-Cyprus Symposium - Receptor Chemistry: Reality and Vision 236
Novel 1,4-dioxane derivatives as NMDA receptor channel blockers 235
Discovery of Highly Selective Imidazoline Receptor Ligands 232
Role of the NMDA Receptor in the Antitumor Activity of Chiral 1,4-Dioxane Ligands in MCF-7 and SKBR3 Breast Cancer Cells 231
77-LH-28-1 as a model for the rational design of selective dopamine D4 receptor ligands 229
Structure-activity relationships in 1,4-benzodioxan-related compounds. 7. Selectivity of 4-phenylchroman analogues for alpha(1)-adrenoreceptor subtypes 228
Structure−Activity Relationships in 1,4-Benzodioxan-Related Compounds. 11.1 Reversed Enantioselectivity of 1,4-Dioxane Derivatives in α1‑Adrenergic and 5‑HT1A Receptor Binding Sites Recognition 228
Novel Highly Potent and Selective σ1 Receptor Antagonists Related to Spipethiane 226
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders 224
Muscarinic subtypes profile modulation within a series of new antagonists, bridged bicyclic derivatives of 2,2-diphenyl-[1,3]-dioxolan-4-ylmethyl-dimethylamine 222
Rapid novel divergent synthesis and muscarinic agonist profile of all four optical isomers of N,N,N-trimethyl(6-methyl-1,4-dioxan-2-yl)methanaminium iodide. 221
Synthesis and muscarinic properties of (1S*,3R*,5R*)-trimethyl(1-methyl-6-oxabicyclo[3.1.0]hex-3-yl)methyl ammonium iodide 221
Design, Synthesis and Biological Evaluation of Novel Chemical Entities as Potential Anticancer Drugs and for the Control of the Metastatic Process 220
Low doses of allyphenyline and cyclomethyline, effective against morphine dependence, elicit an antidepressant-like effect 220
Topical antiinflammatory activity of complexes of escin and sterols with phospholipids. Part I. 219
31st Camerino-Cyprus-Noordwijkerhout Symposium - Receptor Chemistry Skyline 219
Dopamine D-5 receptors: A challenge to medicinal chemists 219
16th Camerino-Noordwijkerhout Symposium - An Overview of Receptor Chemistry 218
Alpha(2)-Adrenoreceptors Profile Modulation. 3. (R)-(+)-m-Nitrobiphenyline, a New Efficient and alpha(2C)-Subtype Selective Agonist. 217
Homoazanicotine: A structure-affinity study for nicotinic acetylcholine (nACh) receptor binding 216
Might Adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine? 216
Chemical manipulations on the 1,4-dioxane ring of 5-HT1A receptor agonists lead to antagonists endowed with antitumor activity in prostate cancer cells 214
Use of frozen sections for the pharmacological characterization of compounds active on neurotransmitter receptors 212
28th Camerino-Cyprus-Noordwijkerhout Symposium - Trekking through Receptor Chemistry 212
Alpha(2)-adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole 211
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation 211
Enantioselective interactions to improve adrenergic α2C-agonism/α2A-antagonism 209
4WD to Travel Inside the 5-HT1A Receptor World 208
NOVEL BIVALENT LIGANDS OF XANOMELINE AND 77-LH-28-1 AS POTENTIAL M1 MUSCARINIC AGONISTS 206
Potent muscarinic antagonists bearing 1,4-dioxane scaffold 205
Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity 204
TESTING D2-LIKE RECEPTOR AFFINITY AND SELECTIVITY WITH NOVEL IMIDAZOLINE DERIVATIVES 203
Novel Potent 5-HT1a Agonists Selective over alpha1-Adrenoceptor Subtypes 203
Chain-lengthened and imidazoline analogues of nicotine 202
Synthesis and Biological Evaluation of a Novel Series of Heterobivalent Muscarinic Ligands Based on Xanomeline and 1‑[3- (4-Butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77- LH-28-1) 202
Solution-phase synthesis of ICG-001, a beta-turn peptidomimetic molecule inhibitor of beta-catenin-Tcf-mediated transcription 201
Dioxane and Oxathiane Nuclei: Suitable Substructures for Muscarinic Agonists 200
Structure-activity relationships in 1,4-benzodioxan-related compounds. 9.From 1,4-benzodioxan to 1,4-dioxane ring as a promising template of novel alpha(1D)-adrenoreceptor antagonists, 5-HT1A full agonists, and cytotoxic agents. 200
Muscarinic Thioligands with Cyclopentane Nucleus 199
Fruitful Adrenergic alpha(2C)-Agonism/alpha(2A)-Antagonism Combination to Prevent and Contrast Morphine Tolerance and Dependence 198
Allyphenyline analogues potentially useful in the management of chronic pain and opioid addiction. 198
Ligand binding to I2 imidazoline receptor: the role of lipophilicity in quantitative structure-activity relationship models 198
Synthesis and dopamine receptor affinities of 2-(4-fluoro-3-hydroxyphenyl)ethylamine and N-substituted derivatives 197
alpha(2)-adrenoreceptors profile modulation. 4. From antagonist, to agonist behavior 197
DOPAMINE D2, D3, AND D4 RECEPTOR AFFINITIES OF 77-LH-28-1 AND ITS ANALOGUES 197
Synthesis, Absolute Configuration, and Biological Profile of the Enantiomers of trans-[2-(2,6-Dimethoxypheoxy)ethyl] [(3-p-tolyl-2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amine (Mephendioxan), a Potent Competitive alpha 1A-Adrenoreceptor Antagonist 196
Novel muscarinic acetylcholine receptor hybrid ligands embedding quinuclidine and 1,4-dioxane fragments 196
Structure-activity relationships in 1,4-benzodioxan-related compounds. 8.(1) {2-[2-(4 chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha1D- and alpha1B-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation 194
Synthesis and Structure-Activity Relationship Studies in a Series of 2-Substituted 1,3-Dioxolanes Modified at the Cationic Head. 192
Synthesis, molecular modeling, and pharmacological testing of bis-quinolinium cyclophanes: Potent, non-peptidic blockers of the apamin-sensitive Ca2+-activated K+ channel 192
Assessing the role of ghrelin and the enzyme ghrelin O-acyltransferase (GOAT) system in food reward, food motivation, and binge eating behavior 192
Agonists and antagonists targeting the different alpha(2)-adrenoceptor subtypes 191
Evaluation of an Agonist Index: Affinity Ratio for Compounds Active on Muscarinic Cholinergic M2 Receptors 191
Pharmacophore development and 3D-QSAR study of I1 imidazoline binding site ligands 191
Novel highly potent and selective sigma1 receptor antagonists effectively block the binge eating episode in female rats 190
Synthesis and pharmacological testing of polyaminoquinolines as blockers of the apamin-sensitive Ca2+-activated K+ channel (SKCa) 189
Rational design of novel I1-imidazoline receptor agonists 188
Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma 187
MORPHINE TOLERANCE MODULATION INDUCED BY alpha2-ADRENERGIC OR/AND I2 IMIDAZOLINE BINDING SITES LIGANDS 185
Advances in the Development of Nonpeptide Small Molecules Targeting Ghrelin Receptor 184
Rational design of new alpha(2)-adrenoreceptor agonists 183
Advances in drug design and therapeutic potential of selective or multitarget 5‐HT1A receptor ligands 182
Might adrenergic α2C-agonist/α2A-antagonist become a novel therapeutic multitarget tool for morphine chronic treatment of pain? 182
Synthesis and Muscarinic Receptors Affinity of a series of Antagonist Bivalent Ligands 181
The 2-substituted imidazoline ring linked to an aromatic moiety by a biatomic bridge: a bioversatile scaffold 181
Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity 181
Synthesis and muscarinic activity of some muscarone analogs 177
Totale 24.831
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.439
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.439
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022949 0 0 0 89 109 80 42 98 109 169 87 166
2022/20232.041 240 68 96 297 214 257 14 132 376 121 146 80
2023/20241.438 190 86 95 43 54 132 61 46 146 56 41 488
2024/20254.611 197 100 378 207 127 240 559 1.094 369 292 313 735
2025/20268.135 436 523 1.587 1.048 773 567 1.054 479 445 533 431 259
2026/20272.450 684 232 628 906 0 0 0 0 0 0 0 0
Totale 30.617